期刊文献+

CA125、Cyt-c和MGMT基因在卵巢癌患者血清中的表达及临床意义 被引量:4

The expression and clinical value of serumm carbonhydrate antigen 125,Cytochromes c and MGMT in patients with ovarian cancer
下载PDF
导出
摘要 目的:探讨糖类抗原125(carbohydrate antigen 125,CA125)联合细胞色素C(Cytochromes c,Cyt-c)和O^6-甲基鸟嘌呤-DNA-甲基转移酶(MGMT)在卵巢癌患者血清中的表达情况及临床意义。方法:对53例卵巢癌患者(卵巢癌组)、40例卵巢良性病变患者(卵巢良性病变组)、50例同期体检健康女性(对照组)采用电化学发光法检测血清CA125水平,ELISA法检测Cyt-c水平,甲基化特异PCR法检测MGMT基因启动子甲基化,流式细胞仪检测细胞线粒体膜势能。结果:卵巢癌患者血清中CA125和Cyt-c表达水平明显高于卵巢良性肿瘤组和健康对照组(P<0.05),CA125表达水平在卵巢良性肿瘤组和健康对照组,差异无统计学意义(P>0.05),Cyt-c差异有统计学意义(P<0.05)。MGMT基因启动子在卵巢癌组和卵巢良性肿瘤组中发生甲基化,甲基化率分别为75.3%和21.8%,健康对照组未发生甲基化。结论:联合检测血清CA125、Cyt-c和MGMT基因的表达水平有助于提高早期卵巢癌的诊断效能,对卵巢肿瘤的良恶性鉴别及对预后具有提示作用。 Objective: To investigate the expression of CA125,Cyt-c and O^6-methylguanine DNA methyltransferase( MGMT) and its clinical significance in cervical cancer. Methods: Methylation-specific PCR was used to detect the MGMT methylation status,mitochondrial Transmembrane potentials were examined using flow cytometric analysis. The serum level of CA125 was detected by electro-chemiluminescence,the level of Cyt-c was detected by ELISA respectively in 53 patients with ovarian cancer( cancer group),40 patients with benign ovarian tumor( benign group) and 50 healthy females( control group). Results: The level of CA125 and MGMT methylation status was significantly higher in cancer group than those in benign group and control group,the positive rates were 75. 3% and21. 8% respectively( P〈0. 05). Cyt-c was lower in cancer group than those in benign group and control group.Conclusion: The combined detection of CA125,Cyt-c and MGMT methylation status contributes to improving the diagnosis efficiency,and has a certain application value to the differential diagnosis of benign and malignant ovarian tumor.
作者 薛晓婕 陈婷
出处 《现代肿瘤医学》 CAS 2016年第8期1258-1261,共4页 Journal of Modern Oncology
基金 湖北省自然科学基金项目(编号:2010CDZ054)
关键词 卵巢癌 CA125 CYT-C MGMT ovarian cancer CA125 Cyt-c MGMT
  • 相关文献

参考文献2

二级参考文献24

  • 1焦彦华,王秀艳,刘叶廷.血清CA125、CA72-4、CA199单项检测及联合检测对诊断卵巢癌的临床价值[J].现代养生,2013,0(24):72-72. 被引量:2
  • 2Siegel R,Naishadham D,Jemal A. Cancer statistics,2012 [J]. CA Cancer J Clin, 2012,62( 1 ) : 10-29.
  • 3Gianmaria P,Francesca G. The PDCD4/miR-21 pathway in medullary thyroid carcinoma [J]. Human Pathology,2014, 46( 1 ) : 50-57.
  • 4Lankat-Buttgereit B, Coke R. Programmed cell death pro- tein 4 (pdcd4) :a novel target for antineoplastic therapy [J]. Biol Cell, 2003,95 (8) : 515-519.
  • 5Lankat-Buttgereit B,Goke R. The tumour suppressor Pd- cd4:recent advances in the elucidation of function and regulation [J]. Biol Cell, 2009,101 : 309-317.
  • 6Siegel R,Naishadham D,Jemal A. Cancer statistics,2012 [J]. CA Cancer J Clin,2012,62(1) : 10-29.
  • 7Goff BA,Mandel LS, Melancon CH, et al. Frequency of symptoms of ovarian cancer in women presenting to prim ary care clinics [J]. JAMA, 2004,291(22) : 2705-2712.
  • 8Vikhreva PN, Shepelev MV, Korobko IV, et al. mTOR-de- pendent transcriptional repression of PDCD4 tumor sup- pressor in lung cancer cells [J]. Bioehimica et Biophysica Acta-Gene Regulatory Mechanisms,2014,1839(1) :43--49.
  • 9Motoyama K, Inoue H, Mimori K, et al. Clinicopathological and prognosticsignificance of PDCD4 and micro RNA-21 in human gastric Cancer [J]. Int J Oncol,2010,36(5) : 1089- 1095.
  • 10Mudduluru G,Medved F,Grobholz R,et al. Loss of pro- grammed celldeath 4 expression marks adenoma -carcinoma transition,correlates inversely with phosphorylated protein kinase B, and is an independent,prognostic factor in resect- ed colorectal cancer [J]. Cancer,2007,110(8) : 1697-1707.

共引文献31

同被引文献64

引证文献4

二级引证文献21

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部